Evidence map›Paper›PMID 30897135›Full record

ArticlePloS one2019

Retrospective investigation of antibodies against chikungunya virus (CHIKV) in serum from febrile patients in Mozambique, 2009-2015: Implications for its prevention and control.

Virgilio Santo Antonio, Nádia Alves Amade, Argentina Felisbela Muianga, Sadia Ali, Vanessa Monteiro, Flora Mula, Imelda Chelene, John Oludele, Inocêncio Chongo, Américo José and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Virgilio Santo AntonioVirus Isolation Laboratory, National Institute of Health, Maputo, Mozambique.
Nádia Alves AmadeVirus Isolation Laboratory, National Institute of Health, Maputo, Mozambique.
Argentina Felisbela MuiangaVirus Isolation Laboratory, National Institute of Health, Maputo, Mozambique.
Sadia AliVirus Isolation Laboratory, National Institute of Health, Maputo, Mozambique.
Vanessa MonteiroVirus Isolation Laboratory, National Institute of Health, Maputo, Mozambique.
Flora MulaVirus Isolation Laboratory, National Institute of Health, Maputo, Mozambique.
Imelda CheleneVirus Isolation Laboratory, National Institute of Health, Maputo, Mozambique.
John OludeleVirus Isolation Laboratory, National Institute of Health, Maputo, Mozambique.ORCID 0000-0002-1874-4150
Inocêncio ChongoVirus Isolation Laboratory, National Institute of Health, Maputo, Mozambique.
Américo JoséPolana Caniço Research and Training Center, National Institute of Health, Maputo, Mozambique.
Orvalho AugustoDepartment of Microbiology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
Eduardo Samo GudoVirus Isolation Laboratory, National Institute of Health, Maputo, Mozambique.ORCID 0000-0002-8686-7873
Eduardo Mondlane University · MZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLongitudinal data and trends about chikungunya virus (CHIKV) are critical for its control, however in Mozambique very few studies were conducted over 5 decades, between 1957 and 2013. In this study, we retrospectively investigated the occurrence, geographical distribution and trend of anti-CHIKV antibodies between 2009 and 2015 in Mozambique using serum samples from febrile patients.

methodsA total of 895 serum samples collected from febrile patients for measles and rubella surveillance between 2009 and 2015 in 127 districts of Mozambique were retrospectively tested for IgM and IgG antibodies against CHIKV using a commercially available ELISA.

resultsThe median age of patients was 2 years (IQR: 1-5 years) and 44.2% (395/895) of them were female. We found that 54 (6.0%) of samples were positive for anti-IgM chikungunya, and 160 (17.9%) were positive for anti-CHIKV IgG. Antibodies against CHIKV (IgM and IgG) were identified in serum throughout 2009 to 2015. While frequency of IgG antibodies was significantly higher in 2015 as compared to other years, frequency of IgM antibodies was homogeneous between 2009 and 2015. Antibodies against CHIKV were reported in all provinces and in 84 (66.1%) of the districts studied. Frequency of IgM and IgG antibodies was not significantly similar between age groups.

conclusionThis is the largest and longest serological screening of antibodies against CHIKV in febrile patients in Mozambique and findings from this study suggest that Mozambicans from all over the country have been silently exposed to CHIKV for several years.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, ViralChikungunya FeverChikungunya virusChildChild, PreschoolFemaleFeverHumansImmunoglobulin GImmunoglobulin MInfantInfant, NewbornAntibodies, ViralImmunoglobulin GImmunoglobulin M

Identifiers

PMID30897135
PMCPMC6428254
OpenAlexW2924659125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.